SecurityCBS / CBS Corp. (124857202)
Chairman, President & CEOMOONVES LESLIE
Form 4 Count915
Form 425 Count89
Form 8-K Count84
Form SC 13G/A Count22

SEC Filings - 10K, 8K, Annual Reports

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CBS Corp.


DateFormTitle
2018-05-22 8-K CBS / CBS Corp. 8-K (Current Report)
2018-05-18 8-K CBS / CBS Corp. null (Current Report)
2018-05-14 8-K CBS / CBS Corp. 8-K (Current Report)
2018-05-04 10-Q CBS / CBS Corp. 10-Q (Quarterly Report)
2018-05-03 8-K CBS / CBS Corp. 8-K (Current Report)
2018-04-06 DEFA14A CBS / CBS Corp. DEFA14A
2018-04-06 DEF 14A CBS / CBS Corp. DEF 14A
2018-03-02 S-4 CBS / CBS Corp. S-4
2018-03-02 S-4 CBS / CBS Corp. S-4
2018-02-20 10-K CBS / CBS Corp. 10-K (Annual Report)
2018-02-15 8-K CBS / CBS Corp. 8-K (Current Report)
2018-02-09 S-8 POS CBS / CBS Corp. S-8 POS
2018-02-08 SC 13G/A CBS / CBS Corp. / VANGUARD GROUP INC - 3G/A (Passive Investment)
2018-02-08 SC 13G/A CBS / CBS Corp. / VANGUARD GROUP INC - 3G/A (Passive Investment)
2018-02-08 SC 13G/A CBS / CBS Corp. / BlackRock Inc. - 3G/A (Passive Investment)
2018-02-08 SC 13G/A CBS / CBS Corp. / BlackRock Inc. - 3G/A (Passive Investment)
2017-05-24 8-K CBS 8-K (Current Report/Significant Event)
2017-05-04 10-Q CBS 10-Q (Quarterly Report)
2017-05-04 8-K CBS 8-K (Current Report/Significant Event)
2017-04-07 DEFA14A CBS DEFA14A
2017-04-07 DEF 14A CBS DEF 14A
2017-03-20 425 CBS 425 (Prospectus)
2017-03-02 425 CBS 425 (Prospectus)
2017-02-17 10-K CBS 10-K (Annual Report)
2017-02-15 8-K CBS 8-K (Current Report/Significant Event)
2017-02-10 SC 13G/A CBS 3G/A (Passive Acquisition of More Than 5% of Shares)
2017-02-10 SC 13G/A CBS 3G/A (Passive Acquisition of More Than 5% of Shares)
2017-02-02 8-K CBS FORM 8-K (Current Report/Significant Event)
2017-02-02 425 CBS FORM 8-K (Prospectus)
2017-02-02 425 CBS 425 (Prospectus)
2017-02-02 8-K CBS 8-K (Current Report/Significant Event)
2017-02-02 425 CBS 8-K (Prospectus)
2017-01-23 SC 13G/A CBS 3G/A (Passive Acquisition of More Than 5% of Shares)
2017-01-23 SC 13G/A CBS 3G/A (Passive Acquisition of More Than 5% of Shares)
2016-11-03 10-Q CBS 10-Q (Quarterly Report)
2016-11-03 8-K CBS 8-K (Current Report/Significant Event)
2016-10-18 8-K CBS FORM 8-K (Current Report/Significant Event)
2016-10-14 8-K CBS 8-K (Current Report/Significant Event)
2016-10-07 8-K CBS 8-K (Current Report/Significant Event)
2016-07-28 10-Q CBS 10-Q (Quarterly Report)
2016-07-28 8-K CBS 8-K (Current Report/Significant Event)
2017-04-09 LETTER CBS ER
2017-04-09 CORRESP CBS ESP
2016-07-11 8-K CBS FORM 8-K (Current Report/Significant Event)
2016-07-07 424B2 CBS FINAL PROSPECTUS SUPPLEMENT (Prospectus)
2017-04-08 424B2 CBS FINAL PROSPECTUS SUPPLEMENT (Prospectus)
2016-07-07 FWP CBS FINAL TERM SHEET
2016-07-06 424B5 CBS PRELIMINARY PROSPECTUS SUPPLEMENT (Prospectus)
2017-04-08 424B5 CBS PRELIMINARY PROSPECTUS SUPPLEMENT (Prospectus)
2017-04-09 LETTER CBS ER

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 124857202